NCT03352869View on ClinicalTrials.gov

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

PHASE4CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

July 1, 2018

Study Completion Date

July 31, 2018

Conditions
Polycystic Ovary SyndromeOverweight and ObesityDisorder of Glucose Regulation
Interventions
DRUG

Exenatide

Use Exenatide for 3 months to treat PCOS

DRUG

Metformin

Use Metformin for 3 months to treat PCOS

Trial Locations (1)

200127

Renji Hospital Department of Endocrinology and Metabolism, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT03352869 - Research of Exenatide for Overweight/Obese PCOS Patients With IGR | Biotech Hunter | Biotech Hunter